A new skin lesion associated with intravenous streptokinase.

Interferon alfa-2b is used as maintenance treatment in patients with multiple myeloma.'Although renal toxicity is rare, mild proteinuria is common.2We present the case of a patient who developed acute renal failure during treatment with recombinant interferon alfa-2b.A 49 year old woman was admitted with a week's history of nausea, vomiting, and declining urinary output.Two years previously an IgG K multiple myeloma had been diagnosed.Ten months before admission maintenance treatment with recombinant interferon alfa-2b (intron A) 3 MU was started sub- cutaneously thrice weekly.She took additionally only ferrous sulphate and vitamin B complex.On admission she was pale and apyrexial, with a blood pressure of 120/70 mmHg, a sinus tachycardia of 100 beats/min, and a central venous pressure of 1 mm H20.Cardiovascular, respiratory, and abdominal examination showed nothing abnormal.Investigations showed: serum sodium 127 mmol/l (normal 136-148), potassium